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Proper Writing of Multiple Schedule II 
Prescriptions
By Mark Mather, RPh, Compliance Officer
Recently, there has been some confusion among pre-
scribers and pharmacists on the proper way to write and 
fill multiple Schedule II prescriptions written for the 
same drug and patient. Let’s start with the overarching 
law, in the Iowa Administrative Code (IAC), which says 
(emphasis added): “657—10.25(124) Schedule II— 
issuing multiple prescriptions. An individual prescriber 
may issue multiple prescriptions authorizing the patient 
to receive a total of up to a 90-day supply of a Schedule 
II controlled substance pursuant to the provisions and 
limitations of this rule.” The subsection of this law that 
pertains to our topic is as follows (emphasis added): 
10.25(3) Dates and instructions. Each pre-
scription issued pursuant to this rule shall be 
dated as of and manually signed by the pre-
scriber on the day the prescription is issued. 
Each separate prescription, other than the first 
prescription if that prescription is intended to 
be filled immediately, shall contain written 
instructions indicating the earliest date on 
which a pharmacist may fill each prescription. 
Many prescribers tend to forget that each prescription 
needs to be signed and dated on the same day the prescrip-
tions are issued. Most currently, there has been confusion 
surrounding the “do not fill dates” required on these Sched-
ule II prescriptions. With the exception of the first month’s 
fill, the prescriber must write on all subsequent Schedule 
II prescriptions the earliest date on which that prescription 
may be filled. It is not sufficient to just write “#1,” “#2,” 
“#3,” etc, on each prescription; there must be a “do not fill 
date” on each subsequent prescription after the first one. If 
there is not a “do not fill date,” the prescription is not valid 
and will need to be rewritten. The pharmacist is not allowed 
to add or change the “do not fill date” on the prescription. 
Lastly, the prescriber may write as many separate Schedule 
II prescriptions, to be filled sequentially, as deemed neces-
sary as long as they do not exceed a 90-day supply. 
Approved Activities: Technicians vs. Interns
By Danielle Watznauer, Pharmacist Intern 
Often there may be confusion as to what the differences 
are regarding what pharmacy technicians and pharmacist 
interns may do within the pharmacy. The greatest differ-
ence lies within activities entailing professional judgment. 
Pharmacy technicians are not authorized to perform tasks 
requiring professional judgment. Such activities include 
interpreting prescription drug orders, conducting pro-
spective drug use review, and performing final product 
verification, except for participation in an approved tech-
check-tech program. Technicians cannot provide patient 
counseling, consultation, or patient-specific drug informa-
tion; tender an offer of patient counseling on behalf of a 
pharmacist; or accept a refusal of patient counseling from 
a patient or patient’s agent. They also cannot transfer a 
prescription to another pharmacy or receive the transfer 
of a prescription from another pharmacy.
Pharmacist interns, however, are allowed to perform 
activities requiring professional judgment. These tasks, 
usually restricted to a pharmacist, may be delegated to 
interns registered by the Iowa Board of Pharmacy at 
the discretion of the supervising pharmacist. These judg-
mental functions include, but are not limited to, verify-
ing the accuracy, validity, and appropriateness of filled 
prescriptions, reviewing and assessing patient records, 
providing patient counseling, and administering vacci-
nations. In addition, interns may answer patient-specific 
drug information questions and transfer a prescription 
into or out of the pharmacy under the pharmacist’s super-
vision. A licensed pharmacist on duty in the pharmacy is 
responsible for all actions of the intern.
Dissolution of Prescriber/Patient 
Relationship
By Melanie Reineke, Pharmacist Intern
It is common for patients to stop seeing a prescriber and 
find a new prescriber without the pharmacist becoming 
aware that the relationship associated with the patient’s 
current refills has ended. However, in the instance of 
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well-known and repetitive dispensing errors. Pharmacies should 
seek out medication safety information and use it proactively to pre-
vent medication errors. At the same time, safety issues recognized 
internally and/or reported by patients should be documented and 
analyzed, with a process to determine the best strategies to prevent 
future problems and methods to ensure implementation. An annual 
survey to assess consumer perceptions of the quality of pharma-
ceutical products and professional services could supply additional 
information upon which to base improvement strategies. For more 
information on CQI programs, visit Section 7 of Model Rules for 
the Practice of Pharmacy in The Model State Pharmacy Act and 
Model Rules of the National Association of Boards of Pharmacy.
Informational tools like the ISMP Medication Safety 
Alert! publication, or ISMP’s Quarterly Action Agenda, which is 
a readily available list of medication problems compiled from the 
nation’s reporting programs, can be a backbone of any CQI effort. 
The very purpose of the ISMP Medication Errors Reporting Pro-
gram  – indeed the purpose of any type of safety reporting program 
and the expert recommendations that stem from it – is to guide the 
implementation of quality improvement initiatives by practitioners 
and organizations. 
It is important that certain information from the CQI proceedings 
and records of review be protected from discovery. Patient safety 
organizations (PSO) are organizations that share the goal of improv-
ing the quality and safety of health care delivery. Patient Safety 
Work Product (PSWP) is the information protected by the privilege 
and confidentiality protections of the Patient Safety Act and Patient 
Safety Rule. PSOs serve as independent, external experts who 
can collect, analyze, and aggregate PSWP locally, regionally, and 
nationally to develop insights into the underlying causes of patient 
safety events, thus improving quality by identifying and reducing 
the risks and hazards associated with patient care. Communications 
with PSOs are protected to allay fears of increased risk of liability 
because of collection and analysis of patient safety events.
For more information on PSOs, visit https://www.pso.ahrq 
.gov/faq.
NCPDP Releases Guide to Ensure Patients 
Get Their Medications During a Disaster
The National Council for Prescription Drug Programs (NCPDP) 
released the NCPDP Emergency Preparedness Information guide 
to assist pharmacists and other health care providers during a 
declared emergency. Prepared by the NCPDP Emergency Pre-
paredness Committee, the guide provides resource information 
for eligibility and claims processing affecting displaced individu-
als. The guide is available at www.ncpdp.org/NCPDP/media/pdf/
NCPDPEmergencyPreparednessInformation_v1_4.pdf. Additional 
information for pharmacists about emergency preparedness is 
available on the NCPDP website at www.ncpdp.org/Resources/
Emergency-Preparedness. 
FDA Warns of Illnesses and Deaths in Pets 
Exposed to Fluorouracil
Food and Drug Administration (FDA) is alerting pharmacists 
that patients’ pets are at risk of illness and death when exposed 
to the topical cancer medication fluorouracil cream USP 5% 
(5-FU) that is intended for use in people. Fluorouracil may 
also be marketed under the brand names Carac®, Efudex®, and 
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WHO Launches Global Patient Safety 
Challenge on Medication Safety
To reduce severe, avoidable medication-associated harm in 
all countries by 50% over the next five years, the World Health 
Organization (WHO) has launched a worldwide initiative, the 
Global Patient Safety Challenge on Medication Safety. Medication 
errors cause at least one death every day and injure approximately 
1.3 million people every year in the United States. In addition, low- 
and middle-income countries are estimated to have similar rates 
of medication-related adverse events as high-income countries.
The Global Patient Safety Challenge on Medication Safety aims 
to make improvements in each stage of the medication use process 
including prescribing, dispensing, administering, monitoring, and 
use. WHO intends to provide guidance and develop strategies, in 
addition to plans and tools to ensure that the medication process 
has the safety of patients at its core in all health care facilities. 
Previous WHO Global Safety Challenges have included the 
Clean Care is Safer Care challenge on hand hygiene in 2005 
and the Safe Surgery Saves Lives challenge in 2008. Additional 
information is available in the WHO press release available at 
http://who.int/mediacentre/news/releases/2017/medication-related-
errors/en.
Continuous Quality Improvement and Patient 
Safety Organizations 
This column was prepared by the Institute 
for Safe Medication Practices (ISMP). ISMP 
is an independent nonprofit agency and 
federally certified patient safety organization 
that analyzes medication errors, near misses, and potentially 
hazardous conditions as reported by pharmacists and other 
practitioners. ISMP then makes appropriate contacts with 
companies and regulators, gathers expert opinion about prevention 
measures, and publishes its recommendations. To read about the risk 
reduction strategies that you can put into practice today, subscribe 
to ISMP Medication Safety Alert!® Community/Ambulatory Care 
Edition by visiting www.ismp.org. ISMP provides legal protection 
and confidentiality for submitted patient safety data and error 
reports. Help others by reporting actual and potential medication 
errors to the ISMP National Medication Errors Reporting Program 
Report online at www.ismp.org. Email: ismpinfo@ismp.org.
Data from the ISMP Medication Errors Reporting Program 
reveals that medication-related problems are repetitive in nature. 
An incident of misuse in one setting is likely to repeat itself in 
another. Most importantly, the system changes that are necessary 
to prevent errors are similar, and a growing body of literature is 
available to guide these efforts. Tragically, too many organizations 
and individual providers do not believe similar incidents could hap-
pen to them. They fail to use information about errors occurring 
elsewhere as a roadmap for improvement in their own organization 
or practice. It is not until a serious error hits home that aggressive 
prevention efforts are implemented. With so much evidence-based 
information about error prevention at hand, there is little excuse 
for reacting to errors after they happen instead of preventing them. 
The development and implementation of continuous quality 
improvement (CQI) efforts should be the highest priority in all 
pharmacies. Such efforts must be aimed specifically at preventing 
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Fluoroplex®. Very small amounts could be dangerous to household 
pets; thus, patients should use care when applying and storing the 
medication. FDA has received reports of five dogs that became 
ill and died after accidentally ingesting the topical cream, notes 
a Center for Veterinary Medicine Update available at www.fda 
.gov/AnimalVeterinary/NewsEvents/CVMUpdates/ucm537434.htm. 
Although FDA has not received any reports involving cats to 
date, cats are also expected to be extremely sensitive to fluorouracil 
cream. For instance, if an owner applies fluorouracil cream to an 
afflicted area and touches his or her cat, the cat may accidentally 
ingest the medication when grooming itself and suffer adverse 
events. 
FDA advises that pharmacists who fill these prescriptions 
should advise patients with pets to prevent exposing their pet to 
the medication. Adverse events may be reported to FDA using 
the Form FDA 1932a, which may be obtained at www.fda.gov/
AnimalVeterinary/SafetyHealth/ReportaProblem/ucm055305.htm. 
FDA Revises Final Guidance Documents on 
Bulk Drug Substances Used in Compounding
In January 2017, FDA issued revised versions of two final 
guidance documents regarding the use of bulk drug substances in 
compounding.
 ♦ Interim Policy on Compounding Using Bulk Drug Sub-
stances Under Section 503A of the Federal Food, Drug, and 
Cosmetic Act
 ♦ Interim Policy on Compounding Using Bulk Drug Sub-
stances Under Section 503B of the Federal Food, Drug, and 
Cosmetic Act 
FDA clarified that the policies described in the guidances do not 
apply to inactive ingredients. Inactive ingredients are not included 
in the definition of a “bulk drug substance” and can be used in 
compounding without appearing on the bulk drug substances lists 
developed under sections 503A or 503B of the Federal Food, Drug, 
and Cosmetic Act, if all applicable conditions are met. 
As indicated on its website at www.fda.gov/Drugs/DrugSafety/
ucm502075.htm, FDA will also provide regular updates to the cat-
egories of bulk drug substances described in the guidances. FDA 
previously stated that it would not evaluate new nominations for 
placement in one of the three categories until after it completed its 
review of substances already nominated with adequate supporting 
information. 
Now, the guidances state that FDA will determine after submis-
sions are received whether new nominations, including renomina-
tions of substances with additional supporting information, have 
sufficient information for FDA to review them. After making 
that determination, FDA will place nominated substances in the 
appropriate category on FDA’s website. FDA intends to update 
the categories with any new nominations the first business day of 
each month. This revised policy will further minimize unnecessary 
disruptions to patient treatment while FDA develops the lists of 
bulk drug substances for use in compounding. 
The guidances are available online at www.fda.gov/downloads/
Drugs/GuidanceComplianceRegulatoryInformation/Guid-
ances/UCM469120.pdf and www.fda.gov/downloads/Drugs/ 
GuidanceComplianceRegulatoryInformation/Guidances/
UCM469122.pdf. 
APhA Resource Guide Applies JCPP 
Pharmacists’ Patient Care Process to 
Immunization Services
The American Pharmacists Association (APhA) published 
a resource guide that applies the Joint Commission of Phar-
macy Practitioners (JCPP) Pharmacists’ Patient Care Process to 
pharmacy-based immunization services. The components of the 
Pharmacists’ Patient Care Process to collect, assess, plan, imple-
ment, and follow-up should be implemented as routine practice 
along with the National Vaccine Advisory Committee Standards 
for Adult Immunization Practice, as noted in the resource guide, 
Applying the Pharmacists’ Patient Care Process to Immuniza-
tion Services. “[P]harmacists and other vaccine providers need to 
strive to constantly improve collaboration, communication, and 
documentation,” indicates the APhA guide. For more information, 
visit the APhA Immunization Center at www.pharmacist.com/
immunization-center. 
CPE Training on Older Adult Fall Prevention 
Available Online
Developed in collaboration with the Centers for Disease Con-
trol and Prevention (CDC) and the APhA, the Stopping Elderly 
Accidents, Deaths, and Injuries (STEADI) initiative is offering 
continuing pharmacy education (CPE) training for pharmacists 
to prevent falls in adults 65 and older. The training will provide 
strategies to help pharmacists screen older adults for fall risk, 
conduct medication review and management, and offer patient 
education. To participate in the free online training, “STEADI: The 
Pharmacist’s Role in Older Adult Fall Prevention,” visit the CDC 
website at www.cdc.gov/steadi/training.html for more information. 
New FDA Drug Info Rounds Training Video 
Addresses the Combat Methamphetamine 
Epidemic Act
Drug Info Rounds, a series of online videos by FDA, provides 
important and timely drug information to practicing clinical and 
community pharmacists so they can help patients make bet-
ter decisions. In the latest Drug Info Rounds video, “Combat 
Methamphetamine Epidemic Act,” pharmacists discuss the legal 
requirements for the sale of over-the-counter drug products that 
contain pseudoephedrine. Drug Info Rounds was developed with 
contributions from pharmacists in FDA’s Center for Drug Evalu-
ation and Research (CDER), Office of Communications, Division 
of Drug Information. All Drug Info Rounds videos can be viewed 
on the FDA website at www.fda.gov/Drugs/ResourcesForYou/
HealthProfessionals/ucm211957.htm.
FDA Presents Series of CE Webinars for 
Students and Clinicians
FDA’s Division of Drug Information in the CDER presents 
a series of continuing education (CE) webinars targeted toward 
students and health care providers who wish to learn more about 
FDA and drug regulation. The webinars are presented by FDA 
staff and allow participants to interact with staff. Previous webinar 
topics have included an overview of FDA’s role in medication er-
ror prevention and prescription drug labeling. The webinars and 
presentation slides can be accessed on FDA’s website at www.fda 
.gov/DDIWebinars.
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advanced notice of a prescriber’s relocation/termination, 
the pharmacist needs to decide the appropriate reaction 
in order to optimize patient safety. 
Iowa Board of Pharmacy rule IAC 657—8.20(155A) 
states that prescriptions are only valid while a prescriber/
patient relationship exists. However, it also allows for 
prudent judgment (by the pharmacist) based on individual 
circumstances to ensure continuity of therapy until the 
patient can obtain a relationship with a new provider. 
There are many instances where an interruption in 
therapy is dangerous to patient safety, and unfortunately, 
they often overlap with the type of prescriber who is 
hard for patients to gain access to, such as neurologists 
and mental health practitioners. For example, if a patient 
has an appointment with a new prescriber that is a few 
months away, it is justifiable to continue using the patient’s 
current refills from the previous prescriber to avoid an 
interruption in therapy if the patient has a history with 
the pharmacy and is stable on the medications in question. 
Perils From the 2017 DEA PDAC: Pharmacy 
Robberies and Burglaries
By Chris Caracci, Pharmacist Intern 
On July 16, 2017, United States Drug Enforcement 
Administration (DEA) hosted a pharmacy diversion 
awareness conference (PDAC) in Des Moines, IA. During 
this conference, DEA Task Force Officer Frank Magel, 
from the Tactical Diversion Squad in St Louis, MO, dis-
cussed DEA’s policy and procedures for robberies and 
what to do to prevent them from occurring. Below is a 
summary of suggestions made by Officer Magel and DEA. 
These are recommendations based on DEA’s experience 
with burglaries and robberies. 
The most important aspect during any robbery is to 
ensure the safety of the community, your employees, and 
yourself. You should never resist the robber or burglar 
but should always follow their orders. To mitigate any 
potential harm, never try to stop the burglar yourself; 
avoid any sudden movements and wait for law enforce-
ment. Additionally, you should try to make mental notes of 
any physical aspects of the robber that can be used when 
talking to local law enforcement later. Some things to 
try to remember would be the robber’s race, approximate 
height and weight, piercings, tattoos, hair, clothes, skin or 
physical deformities, and shoes. Try to write these notes 
down as quickly as possible after the incident to avoid 
forgetting any important details.  
After a robbery, make sure to get treatment for any 
individuals who may have been harmed. You should try 
to sound an alarm or contact the authorities as soon as 
possible. Lock the store to prevent anyone else from enter-
ing the scene and tampering with any potential evidence, 
such as fingerprints. Ask customers who witnessed the 
robbery to stick around until law enforcement arrives to 
provide any additional testimony about what they wit-
nessed. Document what was stolen from the pharmacy 
and fill out all required paperwork to comply with local, 
state, and federal regulations.
Thieves and burglars often target people or locations 
with weaker security. The more security measures you 
have in place and the more prepared you are, the less 
likely you are to be a target. The following are some tips 
you can follow to help prevent robberies from occurring:
 ♦ Install an alarm system and make sure to test it 
frequently.
 ♦ Utilize security cameras that give you good vis-
ibility of all areas of the pharmacy. Make sure to 
put up visible signage stating that the area is under 
surveillance. 
 ♦ Install a panic button and use it as soon as you see a 
thief escaping out the door.
 ♦ Give local police departments a store discount so 
they may establish a more pronounced presence in 
the store. This deters thieves from targeting a store 
with frequent visits from law enforcement. You can 
also invite law enforcement to conduct a security 
assessment of the pharmacy.
 ♦ Install height markers at exits to the store and also 
near the pharmacy area. These can help witnesses 
take note of the thief’s height and may also tend to 
deter targeting by thieves.
 ♦ Use appropriate physical layouts for the pharmacy. 
For example, banks do not display money; likewise, 
avoid displaying medications. 
 ♦ Conduct criminal background checks on every 
pharmacy employee. 
 ♦ Greet customers as they enter the pharmacy. The 
more attentive the pharmacy staff is, the more likely 
thieves will be deterred from targeting the pharmacy.
 ♦ Be vigilant of any suspicious behavior, including 
individuals spending a lot of time around the phar-
macy without buying anything.
Nonresident Pharmacy PIC Registration 
Required for 2018
By Chris Caracci, Pharmacist Intern
The Board recently approved new rules regarding 
nonresident pharmacy practice that will become effective 
September 6, 2017, and enforceable beginning January 1, 
2018. Beginning with calendar year 2018, the pharmacist-
in-charge (PIC) at every nonresident pharmacy will be 
required to register with the Board. This registration will 
be a one-year registration that will begin on January 1 of 
the calendar year and expire on December 31 of the same 
year. Nonresident pharmacies are those that are located 
outside of the state of Iowa that deliver, dispense, or dis-
tribute prescription drugs or devices to an ultimate user 
who is physically within the state of Iowa. 
This adaptation of the current process does not require 
Iowa licensure for the PIC, but will increase the acces-
sibility for the Board to contact the PIC at the nonresident 
pharmacy. In the past, the Board has had some difficulty 
contacting the PIC at some nonresident pharmacies due 
to frequent staffing changes. The change will also require 
completion of an educational training module regarding 
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the Iowa rules as they relate to nonresident pharmacy 
practice. The Board is currently in the process of creat-
ing this module. 
The application itself will require basic information 
about the PIC, including name and contact information, 
the pharmacist’s license or registration number in the state 
the nonresident pharmacy is located, verification that the 
license is current and in good standing, the PIC’s current 
place of employment, and any criminal and disciplinary 
history information. It will also require a $75 nonrefund-
able administrative fee for processing. Similar to resident 
pharmacies in the state, a change in the PIC requires sub-
mission of a new application and fee. The pharmacy must 
submit notification of a temporary PIC within 10 days of 
the change, and a permanent PIC must be identified and 
registered with the Board no later than 90 days follow-
ing the vacancy. Any changes in PIC information (name, 
contact information, home state license or registration 
status, and place of employment) must be reported to the 
Board in writing within 10 days of the change. Currently, 
there are approximately 1,000 nonresident pharmacies in 
the state of Iowa.
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